Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -42,018 | -22,634 | -4,569 | 212 | 1,385 |
| Depreciation Amortization | 9 | 9 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -2,920 | 4,809 | 777 | -117 | -115 |
| Other Working Capital | -580 | 10,373 | 3,823 | 1,769 | -49 |
| Other Operating Activity | 13,646 | 18,108 | -838 | -2,431 | -1,615 |
| Operating Cash Flow | $-31,863 | $10,665 | $-806 | $-566 | $-394 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | -221 | N/A | N/A | N/A |
| Investing Cash Flow | $-7 | $-221 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,392 | 396,952 | N/A | N/A | N/A |
| Other Financing Activity | 0 | -5,047 | -45 | -45 | -45 |
| Financing Cash Flow | $2,392 | $391,905 | $-45 | $-45 | $-45 |
| Exchange Rate Effect | 3,062 | 5,248 | N/A | N/A | N/A |
| Beginning Cash Position | 467,728 | 60,131 | 1,227 | 1,227 | 1,227 |
| End Cash Position | 441,312 | 467,728 | 376 | 615 | 788 |
| Net Cash Flow | $-26,416 | $407,597 | $-851 | $-611 | $-439 |
| Free Cash Flow | |||||
| Operating Cash Flow | -31,863 | 10,665 | -806 | -566 | -394 |
| Capital Expenditure | -7 | -221 | N/A | N/A | N/A |
| Free Cash Flow | -31,870 | 10,444 | -806 | -566 | -394 |